1	Differential expression of plasma proteins in pregnant women exposed to Plasmodium falciparum
2	malaria
3	
4	Bernard N. Kanoi <sup>1*</sup> , Harrison Waweru <sup>1</sup> , Francis M. Kobia <sup>1</sup> , Joseph Mukala <sup>2</sup> , Peter Kirira <sup>3</sup> , Dominic
5	Mogere <sup>2</sup> , Radiosa Gallini <sup>4</sup> , Mikael Åberg <sup>5</sup> , Manu Vatish <sup>6</sup> , Jesse Gitaka <sup>1*#</sup> , Masood Kamali-
6	Moghaddam <sup>4*#</sup>
7	
8	<sup>1</sup> Centre for Malaria Elimination, Institute of Tropical Medicine, Mount Kenya University, Thika, Kenya
9	<sup>2</sup> School of Public Health, Thika, Kenya
10	<sup>3</sup> School of Pure and Applied Sciences, Mount Kenya University, Thika, Kenya
11	<sup>4</sup> Department of Immunology, Genetics & Pathology, Science for Life Laboratory, Uppsala University,
12	Uppsala, Sweden
13	<sup>5</sup> Unit of Affinity Proteomics Uppsala, Science for Life Laboratory, Sweden; Department <sup>5</sup> Department of
14	Medical Sciences, Section of Clinical Microbiology, Chemistry and SciLifeLab Affinity Proteomics,
15	Uppsala University, Uppsala, Sweden.
16	<sup>6</sup> Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK
17	
18	# Shared senior authorship
19	
20	* Correspondence:
21	Centre for Malaria Elimination, Institute of Tropical Medicine, Mount Kenya University, Thika, Kenya.
22	Bernard Kanoi, <u>bkanoi@mku.ac.ke</u>
23	Centre for Malaria Elimination, Institute of Tropical Medicine, Mount Kenya University, Thika, Kenya.
24	Jesse Gitaka, j <u>gitaka@mku.ac.ke</u>
25	<sup>4</sup> Department of Immunology, Genetics & Pathology, Science for Life Laboratory, Uppsala University,
26	Uppsala, Sweden, Masood Kamali-Moghaddam, <u>masood.kamali@igp.uu.se</u>

#### 27 Abstract

28 In sub-Saharan Africa, pregnant women are at greater risk of malaria infection than non-pregnant 29 adult women. The infection may lead to pregnancy-associated malaria (PAM) because of the sequestration 30 of *Plasmodium falciparum*-infected erythrocytes in the placental intervillous space. Although there are 31 several tools for diagnosing malaria infection during pregnancy, including blood smear microscopic 32 examination, rapid diagnostic tests, and PCR, there are no tools for detecting placental infection and, by 33 extension, any dysfunction associated with PAM. Thus, PAM, specifically placental infection, can only be 34 confirmed via postnatal placental histopathology. Therefore, there is an urgent need for specific serum 35 biomarkers of PAM. Here, we used the high throughput proximity extension assay to screen plasma from 36 malaria-exposed pregnant women for differentially expressed proteins that can predict PAM or adverse 37 malaria outcomes. Such biomarkers may also elucidate the pathophysiology of PAM. We observed that the 38 IgG Fc receptor IIb (Uniprot ID P31994) and HO-1 (P09601) are consistently highly expressed in malaria-39 positive samples compared to samples from malaria-negative pregnant women. On the contrary, NRTN 40 (Q99748) and IL-20 (Q9NYY1) were differentially expressed in the malaria-negative women. IL-20 41 exhibited the highest discriminatory power (AUC = 0.815), indicating a strong association with malaria 42 status. These proteins should be considered for further evaluation as biomarkers of malaria-induced 43 placental dysfunction in pregnant women. 44

Keywords: Pregnancy-associated malaria, malaria in pregnancy, biomarkers, falciparum malaria,
 proteomics, proximity extension assay

#### 47 Introduction

48 Pregnant women in most tropical areas are at an increased risk of malaria because of the placental 49 sequestration of *Plasmodium falciparum* (P. falciparum)-infected red blood cells, which can lead to 50 stillbirth and low birth weight [1]. Despite the availability of numerous diagnostic tools for detecting 51 malaria during pregnancy, there is a lack of a definitive test for determining actual placental infection and 52 dysfunction within the context of pregnancy-associated malaria (PAM) [2]. PAM has several similarities 53 with pre-eclampsia, for which several biomarkers of placental stress and dysfunction have been identified 54 [3,4]. While some of these biomarkers are inflammatory markers that lack specificity, others, such as s-55 endoglin and sFlt1, which are elevated in peripheral blood during pre-eclampsia, appear more specific to 56 placental dysfunction [5]. The predictive value of such biomarkers should be evaluated in the context of 57 PAM to determine their effectiveness as indicators of PAM-associated placental infection and dysfunction 58 [6]. This is crucial for enhancing the diagnosis of typically sub-microscopic malaria infections and malaria-59 induced placental dysfunction, thereby facilitating timely intervention in pregnant women. Indeed, 60 comprehension of disease biology and the interaction between the malaria parasite and the human host is 61 crucial for developing diagnostic, prognostic, and uncovering predictive biomarkers for PAM [7]. 62 Elucidating the expression patterns of plasma proteins can provide insights into how PAM affects placental, 63 maternal, or fetal wellbeing [6,8].

64

65 The rapid development of proteomics platforms, such as multiplex proximity extension assay 66 (PEA), offers highly effective, high-throughput strategies for studying malaria-associated molecular 67 pathophysiological changes [9]. PEA technology enables simultaneous measurement of a large number of 68 proteins using minute amount of sample [7,10]. Studies using this approach have demonstrated its clinical 69 utility in identifying important biomarkers for various diseases, including cancer, long COVID, ischemic 70 stroke, and early pregnancy bleeding [10-15]. In this study, we used PEA to screen sera from pregnant, 71 malaria-exposed women to identify differentially expressed proteins. Using this strategy, we identified four 72 proteins significantly differentially expressed in samples from malaria-infected pregnant women compared 73 with non-infected pregnant counterparts, suggesting that their alteration is P. falciparum-driven. Such 74 proteins can potentially develop into biomarkers of PAM or adverse malaria outcomes.

75 Material and methods

76

78

#### 77 Study design & population.

79 This study used serum samples collected from women between 12 and 18 weeks of gestation. These 80 women were enrolled in the study during their routine antenatal clinic visits at Webuye County Hospital in 81 Bungoma County, Kenya, a region characterized by high malaria transmission [16]. The study protocol and 82 the use of this well-characterized biobank of samples were approved by the Independent Ethics Research 83 Committee (IERC) of Mount Kenya University (No# MKU/IERC/0543, MKU/IERC/2461). The enrolled 84 cohort consisted of women undergoing routine intermittent preventive malaria treatment in pregnancy 85 (IPTp) with sulfadoxine-pyrimethamine (IPTp-SP) [17]. All study participants gave written informed 86 consent before joining the study. The study protocol complied with the International Conference on 87 Harmonization Good Clinical Practices and the Declaration of Helsinki guidelines [18]. Serum samples 88 were collected 4 weeks after IPTp administration and frozen immediately, and then transported on dry ice 89 to the Centre for Malaria Elimination laboratories at Mount Kenya University and immediately stored in a 90 -80°C deep freezer without cold-chain interruption. Each serum sample was matched with corresponding 91 anonymized demographic and pregnancy outcome data. Data on pregnancy progress and outcomes were 92 collected during the scheduled and unscheduled visits. Malaria diagnosis was performed using both 93 microscopy and a ParaCheck Rapid Diagnostic Kit (Orchid Biomedical Systems, India).

94

#### 95 Protein abundance measurement by multiplex proximity extension assay

96 Multiplex PEA technology was used to analyze protein expression in the sera samples using the 97 Olink Inflammation and Cardiovascular II protein panels (Olink<sup>™</sup> Proteomics, Uppsala Sweden, 98 https://olink.com), loading 1µL sample/panel. These panels were selected since they target inflammatory 99 and vascular pathophysiological proteomic signatures, which were hypothesized to be altered by PAM. In 100 PEA, each target protein is recognized by two antibodies attached to single-stranded DNA oligonucleotide 101 [11]. When a pair of antibodies binds to the same target protein, the conjugated DNA oligonucleotides are 102 brought in proximity and hybridize to each other. Subsequently, the DNA molecules are extended to form 103 a double-stranded DNA as template for quantitative PCR amplification [11]. The results are presented as 104 normalized protein expression (NPX) values, which are arbitrary units on a log2 scale, where a one-unit 105 increase in NPX corresponds to a two-fold increase in protein concentration. The limit of detection (LOD) 106 for each protein was determined based on three times the standard deviation (SD) above the NPX value of 107 the negative controls in each run. In this study, a total of 183 different proteins were measured, where each

108 panel included 92 proteins involved in diverse biological processes and 4 technical controls. Analyses were 109 performed at the Clinical Biomarker Facility at SciLifeLab, Uppsala University.

110

#### 111 Data analysis

112 Data analyses were performed using R software (www.r-project.org). Normalized protein 113 expression (NPX) values were used for analysis because they tend to follow a normal distribution. Samples 114 from malaria infected group and the controls were randomized within the plates to minimize variability 115 between plates. The inter-plate variation was further normalized for each protein in each plate by adding a 116 z-score factor, which was calculated as follows: factor = (actual value - median of all samples) / standard 117 deviation. To compare malaria cases and controls, NPX values were adjusted if a significant effect (adjusted 118 p value < 0.05) for age on protein levels was found by linear regression in both the control and malaria 119 groups.

120 For univariate analysis, the difference in protein levels between the malaria and non-malaria groups 121 was examined using linear regression, using age and gravida as covariates. The dependent variable was 122 NPX, and the independent variables were malaria status. The likelihood ratio test was used to assess the 123 significance of the difference. The statistical significance of the differences between two groups was 124 determined for continuous variables using the Mann-Whitney-Wilcoxon test. For categorical variables, the 125 Chi-square or Fisher's exact test was used. The analysis of variance (ANOVA) test was used to compare 126 more than two groups. The paired Mann-Whitney-Wilcoxon test was used to compare different malaria 127 groups. Spearman's rank rho was used to test the correlation coefficients or collinearity between each 128 protein marker and other continuous variables. The Bonferroni-Dunn post hoc test was used to correct for 129 multiple testing by adjusting the p-values for false discovery rate. A difference was considered significant 130 if the q-value (adjusted p-value) was less than 0.05.

131 Additionally, elastic-net penalized logistic regression (ENLR) was used to identify a combination 132 of analytes that could improve the discrimination between cases and controls. ENLR applies a penalty to 133 the regression coefficients and finds groups of correlated variables. The optimal penalization proportion  $\alpha$ 134 was determined using grid search with a 10-fold cross-validation. The optimal tuning parameter  $\lambda$  was 135 determined as the mean value of 100 iterative lambda values that minimized the model's deviance. The 136 regression coefficients were used to assess the contribution of individual proteins to the case-control 137 discrimination. The ENLR model was estimated using the R package glmnet [19]. The regression 138 coefficients for the selected proteins were then calculated by rerunning ENLR with only proteins with non-139 zero coefficients after 10 repetitions. To determine the number of proteins required to predict PAM, ROC

- 140 curves were generated while adding one more protein at a time and then compared with the first ROC curve.
- 141 This process was repeated until none of the ROC curves showed significant improvement.
- 142 **Results**
- 143

#### 144 *Protein reactivity*

145 PEA is optimal for quantification of the levels of soluble plasma proteins in small sample volumes. 146 Here, to identify proteins that might indicate *P. falciparum* infection during pregnancy, we probed the Olink 147 Target 96 Inflammation and Olink Target 96 Cardiovascular II Panels (Table S1) using serum samples 148 collected from 50 women, who were sampled at three different timepoints during pregnancy (Table 1). The 149 initial sampling was performed at 12-18 weeks of gestation and two more samples were collected one and 150 two months before delivery. Twelve (12) women (median age: 24 years, range: 20–29 years) had malaria 151 infection that was detectable using a rapid diagnostic test. The women in the different groups did not differ 152 significantly in terms of age, gravidity, hemoglobin levels, and gestational age.

- 153
- 154

### 155 Table 1. Characteristics of the women assessed in this study.

	Malaria	No Malaria	Overall	P value	
Characteristics	(n=12)	(n=38)	(n=50)		
Age in years at enrollment, mean (mean, range)	24.0 (20.0 - 29.0)	27.3 (19.0 - 42.0)	26.9 (19.0 - 42.0)	0.7775	
Gestation in weeks (mean, range) <sup>a</sup>	18.7 (10.0 - 26.0)	14.2 (4.0 - 28.0)	21.8 (4.0 - 28.0)	0.005	
Gravida (range)	1.8 (1.0 - 3.0)	2.5 (1.0 - 5.0)	2.3 (1.0 - 5.0)	0.07	
Hemoglobin (mean, IQR, g/dL) <sup>a</sup>	11.5 (7.6 -13.6)	12.8 (9.6 - 15.8)	12.5 (7.6 - 15.8)	0.011	
Random sugar Levels (mean, IQR, mmol/L)	5.4 (4.7 - 6.4)	4.9 (4.0 - 6.5)	5.0 (4.0-6.5)	0.10	

156

<sup>a</sup> Statistically significant between the groups (P<0.05 Mann-Whitney-Wilcoxon test; followed by


158 Bonferroni–Dunn post hoc test); <sup>=</sup>malaria was defined as any parasitemia with or without fever;

159 *IQR* = interquartile range; All participants were of the same ethnicity.

#### 160 Protein reactivity and the characteristic of the sampled women

161 Protein reactivity to the proteomic panels was measured at three different visits per participant. 162 The pattern of expression profiles varied considerably among the volunteers, with most proteins being 163 present at different time points (first, second and third trimester) for most women. However, in about 164 10% of the women, less than 20 proteins were detected (Figure 1).

165



171 To assess if there was any relationship between serum protein levels and participant 172 characteristics, such as age, gravida, and gestational age, we conducted a correlation analysis to each 173 of these parameters against the NPX for each protein. Although there was no correlation between 174 protein levels and participants' age, overall plasma protein levels were higher in samples from 175 primigravida (first-time pregnant) women when compared with multigravida women (who have had 2-176 5 pregnancies), although the difference did not reach statistical significance (Table S2).


177 We further assessed the relationship between markers of morbidity, including hemoglobin and 178 random blood sugars, and expressed plasma proteins. We observed that 19 proteins were significantly 179 negatively correlated with hemoglobin levels, and 9 proteins with random blood sugar levels 180 (unadjusted P < 0.05). However, the correlations did not remain significant after False Discovery Rate 181 (FDR) adjustments. Our findings suggest that these proteins may have a role in malaria infection 182 or that they may be involved in the development and/or progression of pregnancy 183 complications, such as anemia and/or gestational diabetes.

#### 185 Differential protein expression in malaria vs no malaria women

*NPX/LOD to allow protein-to-protein comparison.* 

Next, we sought to identify differential protein expression in malaria vs non-malaria women.
This analysis showed that 48 proteins were significantly differentially expressed in malaria vs no
malaria women, at least in one of the three clinic visits (**Table S2**). Notably, IgG Fc receptor IIb
(Uniprot ID: P31994) and HO-1 (P09601) were consistently highly expressed in malaria-positive
samples when compared with malaria-negative samples, while NRTN (Q99748) and IL-20 (Q9NYY1)
were consistently highly expressed in sera from malaria-negative women (**Figure 2**). This data suggest
that malaria infection may downregulate or upregulate various proteins.


193



197 198

We therefore sought to assess if the levels of these proteins fluctuated during the antepartum period using samples collected at different pregnancy timepoints. Except for IL-20, whose serum levels reduced during the follow-up period, there was no significant change in the other proteins, suggesting that the initial induction by malaria infection did not alter the levels of these proteins during the followup period. The top differentially expressed proteins are presented in **Figure 3**, and the full protein list is presented in Supplementary **Tables S3**.

205



207 208

209

210

211

Figure 3: Kinetics of protein expression in malaria-infected vs non-malaria-infected women at three time points during the pregnancy  $-1^{st}$  (red),  $2^{nd}$  (green) and  $3^{rd}$  Visit (blue). \* Represent statistical difference between hospital visits, (Kruskal Wallis, P < 0.005).

#### 212 Protein levels could distinguish malaria cases vs controls

213 We also assessed whether a combination of serum proteins could distinguish malaria cases vs 214 controls. This analysis revealed varying predictive performance among the four proteins we examined 215 in relation to malaria status. IL-20 (O9NYY1) protein exhibited the highest discriminatory power (AUC 216 = 0.815), indicating a strong association with malaria status (Figure 4). This suggests that IL-20 217 expression levels serve as a promising biomarker for malaria diagnosis or prognosis. IgG Fc receptor 218 IIb (Uniprot ID: P31994) protein demonstrated moderate discriminatory ability (AUC = 0.717), 219 suggesting a notable but less pronounced association with malaria status compared to IL-20. Similarly, 220 HO-1 (P09601) protein also displayed moderate discriminatory power (AUC = 0.729), indicating some 221 association with malaria status, although not as strong as IL-20. NRTN (Q99748) protein, with the 222 lowest AUC value (AUC = 0.635), showed weaker discriminatory ability compared to the other proteins. 223 Although NRTN expression levels may still have some association with malaria status, the association 224 is less pronounced compared to IL-20, IgG Fc receptor IIb, and HO-1. 225




Figure 4: ROC curves for different protein expression levels in malaria- vs non-malariainfected women. Each protein has been assigned a colour code, as indicated in the legend.

# 231232 Discussion

Accurate tools for diagnosing malaria during pregnancy are urgently needed to guide effective clinical interventions [20]. In this study, we aimed to identify potential markers of malaria infection by using high-throughput PEA technology. We observed that IgG Fc receptor IIb (Uniprot ID, P31994), HO-1 (P09601), NRTN (Q99748) and IL-20 (Q9NYY1) were differentially expressed in sera from malariainfected pregnant women vs from non-malaria-infected controls. Moreover, these proteins may also highlight processes that underlie malaria pathophysiology during pregnancy.

239

240 IgG Fc receptor IIb (FCGR2B, Uniprot ID, P31994), a low affinity immunoglobulin gamma Fc 241 region receptor, has multiple isoforms in macrophages, lymphocytes, and IgG-transporting placental 242 epithelium [21]. It is the only inhibitory Fc receptor that controls many aspects of immune and 243 inflammatory responses [22]. Variations in the gene encoding this protein, such as loss-of-function 244 polymorphism, have implications for autoimmunity and infection, including severe malaria. FCGR2B 245 is involved in several processes, including Fc receptor-mediated immune complex endocytosis, nervous 246 system development, and immune responses [23]. Other studies have identified FCGR2B as a marker 247 of human metastatic melanoma, where its expression impairs the tumor susceptibility to FcgammaR-248 dependent innate effector responses [24]. With the availability of monoclonal antibodies against 249 FCGR2B [25], studies are needed to evaluate its potential as a biomarker of PAM. 250

We also identified HO-1 (heme oxygenase-1) as abundantly expressed in PAM cases. HO-1 plays a crucial role in heme degradation and cellular responses to stress [26]. During pregnancy, HO-1 maintains a balanced immune response and supports healthy placental development [27]. Evidence from a mouse model [27] indicates that it helps protect against oxidative stress and inflammation, which are often elevated in pregnancy-associated conditions. We hypothesize that in the context of pregnancyassociated malaria, HO-1 may play a role in mitigating the adverse effects of the infection by reducing oxidative stress and inflammation.

258

259 Two other proteins that decreased in PAM cases, Neurturin (NRTN) and Interleukin-20 (IL-260 20), deserve further evaluation. NRTN has been implicated in supporting healthy placental growth and 261 development. It is also involved in the regulation of blood vessel formation and trophoblast invasion, 262 which are critical for successful pregnancy outcomes [28]. IL-20 plays a critical role in the development 263 and maintenance of the placenta, as well as in the regulation of trophoblast invasion, angiogenesis and 264 vascular remodeling [29]. Thus, IL-20 downregulation during PAM might contribute to poor pregnancy 265 outcomes. Indeed, disruptions in IL-20 signaling have been associated with adverse pregnancy 266 outcomes [30]. In the context of pregnancy-associated malaria, IL-20 may modulate the inflammatory 267 response and placental immune tolerance, potentially impacting the severity and outcomes of the 268 infection. These molecules need further evaluation.

#### 269

270 The choice of two Olink panels, Inflammation and Cardiovascular II, provided a wide repertoire 271 of proteins with a critical role during pregnancy or with diagnostic capability for assessing malaria 272 infection of the placenta. However, the panels could have excluded other potentially important 273 proteomic targets, and future studies should aim to include a more diverse range of proteins. This study 274 involved a relatively small sample size and was based on a single study center. Hence, these 275 observations warrant further validation using larger, multicenter malaria-in-pregnancy cohorts. Because 276 this study is correlative, future studies will also seek to experimentally validate the involvement of the 277 identified factors in malaria during pregnancy and the underlying mechanisms, which may uncover 278 additional diagnostic and therapeutic strategies.

279

In conclusion, this study identified four proteins that were differentially regulated between malaria and non-malaria women. Through further investigation, expression of these proteins could potentially be validated for diagnosis of pregnancy-associated malaria.

283 A	cknowled	lgements
-------	----------	----------

We appreciate the study volunteers from Webuye County Hospital and thank the research teams from Mount Kenya University for their technical assistance in obtaining and processing the field samples.

## 287 Funding

This work was funded by InDevelops u-landsfond InDevelops u-landsfond grant to MKM and JG, African Academy of Sciences to JG, and the Swedish Research Council under the grant 2020-02258 to MKM. BNK is an EDCTP Fellow under EDCTP2 programme supported by the European Union grant number TMA2020CDF-3203-EndPAMAL. BNK has also received support from Terumo Life Science Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

294

#### 295 Competing interests

- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- 298

#### 299 Authors contribution

300 BNK, MKM, MV and JG conceived and designed experiments. FMK, HW, JM, and RG

- 301 conducted experiments. BNK, RG, FMK, and HW analyzed the data. BNK, FMK, and JG wrote the
- 302 manuscript. All authors discussed and edited the manuscript.

#### 303

#### 304 References

- Rogerson SJ, Mwapasa V, Meshnick SR. Malaria in pregnancy: linking immunity and pathogenesis to prevention. Am J Trop Med Hyg 2007;77:14–22.
- Brabin BJ. An analysis of malaria in pregnancy in Africa. Bull World Health Organ
   1983;61:1005–16.
- 309 [3] Brabin BJ, Johnson PM. Placental malaria and pre-eclampsia through the looking glass
  310 backwards? J Reprod Immunol 2005;65:1–15.
  311 https://doi.org/https://doi.org/10.1016/j.jri.2004.09.006.
- Roberts JM, Lain KY. Recent Insights into the Pathogenesis of Pre-eclampsia. Placenta
   2002;23:359–72. https://doi.org/https://doi.org/10.1053/plac.2002.0819.
- 314 [5] Jena MK, Sharma NR, Petitt M, Maulik D, Nayak NR. Pathogenesis of Preeclampsia and

315 316		Therapeutic Approaches Targeting the Placenta. Biomolecules 2020;10. https://doi.org/10.3390/biom10060953.
317 318 319	[6]	Gueneuc A, Deloron P, Bertin GI. Usefulness of a biomarker to identify placental dysfunction in the context of malaria. Malar J 2017;16:1–7. https://doi.org/10.1186/s12936-016-1664-0.
320 321 322	[7]	Acharya P, Garg M, Kumar P, Munjal A, Raja KD. Host-parasite interactions in human malaria: Clinical implications of basic research. Front Microbiol 2017;8:1–16. https://doi.org/10.3389/fmicb.2017.00889.
323 324 325 326	[8]	Unger HW, Ome-Kaius M, Wangnapi RA, Umbers AJ, Hanieh S, Suen CSNLW, et al. Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: A randomised controlled trial. BMC Med 2015;13:1–16. https://doi.org/10.1186/s12916-014-0258-3.
327 328 329 330	[9]	Wik L, Nordberg N, Broberg J, Björkesten J, Assarsson E, Henriksson S, et al. Proximity Extension Assay in Combination with Next-Generation Sequencing for High-throughput Proteome-wide Analysis. Mol Cell Proteomics 2021;20:100168. https://doi.org/10.1016/j.mcpro.2021.100168.
331 332 333	[10]	Dayon L, Cominetti O, Affolter M. Proteomics of human biological fluids for biomarker discoveries: technical advances and recent applications. Expert Rev Proteomics 2022;19:131–51. https://doi.org/10.1080/14789450.2022.2070477.
334 335 336	[11]	Assarsson E, Lundberg M, Holmquist G, Björkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 2014;9. https://doi.org/10.1371/journal.pone.0095192.
337 338 339	[12]	Allan-Blitz L-T, Akbari O, Kojima N, Saavedra E, Chellamuthu P, Denny N, et al. Unique immune and inflammatory cytokine profiles may define long COVID syndrome. Clin Exp Med 2023;23:2925–30. https://doi.org/10.1007/s10238-023-01065-6.
340 341 342 343	[13]	Angerfors A, Brännmark C, Lagging C, Tai K, Månsby Svedberg R, Andersson B, et al. Proteomic profiling identifies novel inflammation-related plasma proteins associated with ischemic stroke outcome. J Neuroinflammation 2023;20:1–11. https://doi.org/10.1186/s12974-023-02912-9.
344 345 346	[14]	Davies MPA, Sato T, Ashoor H, Hou L, Liloglou T, Yang R, et al. Plasma protein biomarkers for early prediction of lung cancer. EBioMedicine 2023;93:1–11. https://doi.org/10.1016/j.ebiom.2023.104686.
347 348 349	[15]	Guterstam YC, Acharya G, Schott K, Björkström NK, Gidlöf S, Ivarsson MA. Immune cell profiling of vaginal blood from patients with early pregnancy bleeding. Am J Reprod Immunol 2023;90:1–13. https://doi.org/10.1111/aji.13738.
350 351	[16]	Platt A, Obala AA, MacIntyre C, Otsyula B, Meara WPO. Dynamic malaria hotspots in an open cohort in western Kenya. Sci Rep 2018;8:1–11. https://doi.org/10.1038/s41598-017-

352 13801-6. 353 Peters PJ, Thigpen MC, Parise ME, Newman RD. Safety and toxicity of [17] 354 sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using 355 intermittent preventive treatment. Drug Saf 2007;30:481-501. 356 https://doi.org/10.2165/00002018-200730060-00003. 357 Dixon JRJ. The International Conference on Harmonization Good Clinical Practice [18] 358 guideline. Qual Assur 1998;6:65-74. https://doi.org/10.1080/105294199277860. 359 Fredriksson S, Gullberg M, Jarvius J, Olsson C, Pietras K, Gústafsdóttir SM, et al. Protein [19] 360 detection using proximity-dependent DNA ligation assays. Nat Biotechnol 2002;20:473-361 7. https://doi.org/10.1038/nbt0502-473. 362 Friedman JH, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models [20] 363 via Coordinate Descent. J Stat Softw 2010;33:1-22. https://doi.org/10.18637/jss.v033.i01. 364 Ding XC, Incardona S, Serra-Casas E, Charnaud SC, Slater HC, Domingo GJ, et al. [21] 365 Malaria in pregnancy (MiP) studies assessing the clinical performance of highly sensitive 366 rapid diagnostic tests (HS-RDT) for Plasmodium falciparum detection. Malar J 367 2023;22:1-15. https://doi.org/10.1186/s12936-023-04445-1. 368 Stuart SG, Simister NE, Clarkson SB, Kacinski BM, Shapiro M, Mellman I. Human IgG [22] 369 Fc receptor (hFcRII; CD32) exists as multiple isoforms in macrophages, lymphocytes and 370 IgG-transporting placental epithelium. EMBO J 1989;8:3657-66. 371 https://doi.org/10.1002/j.1460-2075.1989.tb08540.x. 372 [23] Smith KGC, Clatworthy MR. Europe PMC Funders Group Fc  $\gamma$  RIIB in autoimmunity 373 and infection : evolutionary and therapeutic implications 2014;10:328-43. 374 https://doi.org/10.1038/nri2762.Fc. 375 Bournazos S, Woof JM, Hart SP, Dransfield I. Functional and clinical consequences of Fc [24] 376 receptor polymorphic and copy number variants. Clin Exp Immunol 2009;157:244-54. 377 https://doi.org/10.1111/j.1365-2249.2009.03980.x. 378 Cassard L, Cohen-Solal JFG, Fournier EM, Camilleri-Broët S, Spatz A, Chouaïb S, et al. [25] 379 Selective expression of inhibitory Fcy receptor by metastatic melanoma impairs tumor 380 susceptibility to IgG-dependent cellular response. Int J Cancer 2008;123:2832-9. 381 https://doi.org/10.1002/ijc.23870. 382 [26] Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, et al. Monoclonal 383 antibodies capable of discriminating the human inhibitory Fcy-receptor IIB (CD32B) from 384 the activating Fcy-receptor IIA (CD32A): Biochemical, biological and functional 385 characterization. Immunology 2007;121:392-404. https://doi.org/10.1111/j.1365-386 2567.2007.02588.x. 387 [27] Ozen M, Zhao H, Kalish F, Yang Y, Jantzie LL, Wong RJ, et al. Inflammation-induced 388 alterations in maternal-fetal Heme Oxygenase (HO) are associated with sustained innate

389 390		immune cell dysregulation in mouse offspring. PLoS One 2021;16:1–18. https://doi.org/10.1371/journal.pone.0252642.
391 392 393	[28]	Schumacher A, Zenclussen AC. Effects of heme oxygenase-1 on innate and adaptive immune responses promoting pregnancy success and allograft tolerance. Front Pharmacol 2015;5:1–9. https://doi.org/10.3389/fphar.2014.00288.
394 395	[29]	Morel L, Domingues O, Zimmer J, Michel T. Revisiting the Role of Neurotrophic Factors in Inflammation. Cells 2020;9. https://doi.org/10.3390/cells9040865.
396 397 398 399	[30]	Menon R, Ismail L, Ismail D, Merialdi M, Lombardi SJ, Fortunato SJ. Human fetal membrane expression of IL-19 and IL-20 and its differential effect on inflammatory cytokine production. J Matern Neonatal Med 2006;19:209–14. https://doi.org/10.1080/14767050500440986.